Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NEW YORK, Jan. 24, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of (1) PlasmaTech Biopharmaceuticals, Inc. between March 31, 2015 and June 19, 2015; and/or (2) Abeona Therapeutics Inc. (NASDAQ:ABEO) between June 22, 2015 and December 9, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/abeona-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the science behind Abeona’s proposed gene therapy treatment for Sanfilippo syndrome is unviable; (2) Steven H. Rouhandeh, Abeona’s Executive Chairman and Principal Executive Officer, previously worked for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks; and (3) as a result, Defendants’ statements about Abeona’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On December 12, 2016, analyst firm Mako Research published a report asserting, among other things, that Abeona’s science underpinning its gene therapy approach is unviable and that Rouhandeh previously worked in a position of authority at D. Blech & Co.—a firm named after now-convicted felon David Blech.
If you suffered a loss in Abeona you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
